CBpromise 
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
K562 Cell Line
| General Information | |
| Organism | Homo sapiens, human |
| Cell Line Description | K562 cells were established the first human immortalized myelogenous leukemia line. This cell line is derived from a 53-year-old female chronic myelogenous leukemia patient in blast crisis. They can be used as a highly sensitive target for the in vitro natural killer assay. Recently, studies have shown the K562 blasts are multipotential, hematopoietic malignant cells that spontaneously differentiate into recognizable progenitors of the granulocyte, erythrocyte and monocytic series. |
| Tissue | Bone marrow |
| Morphology | Lymphoblast |
| Disease | Chronic myelogenous leukemia (CML) |
| Age | 53 years |
| Primary | No |
| Gender | Female |
| Product Format | Frozen |
| Growth Mode | Suspension |
| Biosafety Level | 1 Biosafety classification is based on U.S. Public Health Service Guidelines. It is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Applications | Cell culture/growth conditions, stable cell transfection, transient transfection, gene expression, protein expression, protein purification |
| Shipped in | Dry ice |
| Storage Temperature | −196°C |
| Characteristics | |
| Karyotype | 2n = 46 |
| Images |  |
| Antigen Expression | CD7 (25%) |
| Cytogenic Data | The stemline chromosome number is triploid. |
| Mycoplasma | Contamination was eliminated with Ciprobay (ciprofloxacin), then negative in DAPI, microbiological culture, PCR assays |
| Immunology | CD3 -, CD14 -, CD15 +, CD19 -, CD33 +, CD71 +, CD235a + |
| Viruses | ELISA: reverse transcriptase negative; PCR: HBV -, HCV -, EBV -, HHV-8 -, HIV-1 -, HIV-2 -, HTLV-I/II -, MLV -, SMRV - |
| Tumorigenic | Yes |
| Effects | Yes, in nude mice Tumors developed within 21 days at 100% frequency (5/5) in nude mice inoculated subcutaneously with 107 cells. |
| Culture Conditions and Handling | |
| Culture Medium | RPMI 1640 + 2 mM Glutamine + 10% Foetal Bovine Serum (FBS). |
| Morphology | Round large, single cells in suspension |
| Subculturing | Cultures can be maintained by the addition or replacement of fresh medium. Seed out at ca. 0.5 x 106 cells/ml, and maintain at 0.1-1.0 x 106 cells/ml. Viability may be low after thawing, but cells recover during the following 2-3 days. Starting the culture with 20% FBS in 12- or 24-well-plates could be of advantage. |
| Split Ratio | Split 1:3 to 1:5 |
| Harvest | Maximal density at 1.0-1.5 x 106 cells/ml |
| Medium Renewal | Add fresh medium every 2 to 3 days |
| Freeze Medium | Complete culture medium supplemented with 5% (v/v) DMSO |
| Culture Temperature | 37°C |
| Incubation Condition | Carbon dioxide (CO2), 5% |
| Cat.No. | Product Name | Price |
|---|---|---|
| RTA-0008 | K562-TNFalpha Assay Cells | Inquiry |
| CSC-RG1140 | Human CCR3 Validated Stable Cell Line-K562 | Inquiry |
| CSC-RR0033 | Human NFAT Prom/Luciferase/Hyg Reporter Stable Cell Line-K562 | Inquiry |
| CSC-RR0321 | Luciferase Reporter Cell Line-K562 | Inquiry |
| CSC-RR0374 | Luc/GFP Reporter Cell Line - K562 | Inquiry |
| CSC-RT0089 | ATG10 Knockout Cell Line-K562 | Inquiry |
| CSC-RT0100 | TMEM187 Knockout Cell Line-K562 | Inquiry |
| CSC-RO0178 | Cas9 Stable Cell Line-K562 | Inquiry |
| CSC-RT2666 | Human RAPSN Knockout Cell Line-K562 | Inquiry |
| CSC-RT2674 | Human SET Knockout Cell Line-K562 | Inquiry |
| CSC-RO0252 | CD19 Stable Cell Line - K562 | Inquiry |
| CSC-RO0253 | MSLN-2A-GFP Stable Cell Line - K562 | Inquiry |
| CSC-RO0254 | PDCD1 Stable Cell Line - K562 | Inquiry |
| CSC-RR0470 | GFP Reporter Cell Line - K562 | Inquiry |
The above is only part of a part of cell line products. If you don’t find the cell line you want, Creative Biogene can also provide stable cell line generation service with the best prices and fastest turnaround time for you! Contact us for more information or to request a quote.
For research use only. Not intended for any clinical use.